Results 121 to 130 of about 56,324 (305)
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histocytosis and Erdheim-Chester disease [PDF]
, 2017 Erdheim–Chester disease (ECD) is a rare histiocytic disorder, characterized by the xanthomatous infiltration of tissues by CD68-positive and CD1a-/CD100-negative foamy histiocytes. In childhood, ECD is exceptionally rare, and only a dozen cases have been
Bánusz, Rita +6 more
core +2 more sources
Growth of children with Langerhans cell histiocytosis [PDF]
, 1995 Conclusion: GH deficiency is not a common manifestation of LCH in childhood and GH provocation tests are only indicated when there is a poor or decelerating growth rate.
Egeler, R.M. (Maarten) +3 more
core +1 more source
Langerhans cell histiocytosis in adults: a case report and review of the literature
OncoTarget, 2016 Background Langerhans cell histiocytosis (LCH) is a proliferative disease of histiocyte-like cells that generally affects children. Immunohistochemistry is essential to obtain the correct diagnosis, and treatment protocols are controversial.
Cui Lian, Yuan Lu, Siyuan Shen
semanticscholar +1 more source
A Case of Refractory Langerhans Cell Histiocytosis Complicated with Hemophagocytic Lymphohistiocytosis Rescued by Cord Blood Transplantation with Reduced-intensity Conditioning [PDF]
, 2017 We diagnosed a female infant with Langerhans cell histiocytosis (LCH) who was refractory to conventional chemotherapy. She showed refractory inflammation that was complicated with hemophagocytic lymphohistiocytosis (HLH) during LCH chemotherapy ...
Kanamitsu, Kiichiro +4 more
core +1 more source
Proceedings of the Royal Society of Medicine, 1969 S, Bor, I, Smith, M, Feiwel
openaire +2 more sources
Langerhans' Cell Histiocytosis
Dermatology Online Journal, 2002 Adult onset Langerhans cell histiocytosis is uncommon. A 29 year old man is presented who developed classic cutaneous disease with severe systemic involvement. He responded completely to a two month course of thalidomide.
Mortazavi, Hessein +3 more
openaire +4 more sources
Recurrent BRAF mutations in Langerhans cell histiocytosis.
Blood, 2010 Langerhans cell histiocytosis (LCH) has a broad spectrum of clinical behaviors; some cases are self-limited, whereas others involve multiple organs and cause significant mortality.
G. Badalian‐Very +14 more
semanticscholar +1 more source
Multisystem Langerhans cell histiocytosis coexisting with metastasizing adenocarcinoma of the lung: A case report [PDF]
, 2013 Introduction. Langerhans cell histiocytosis (LCH) is an uncommon disease of unknown etiology characterized by uncontrolled proliferation and infiltration of various organs by Langerhans cells. Case report. We presented a 54-year-old man, heavy smoker,
Eri Živka +6 more
core +1 more source
Journal of Indian Society of Periodontology, 2011 Langerhans cell histiocytosis (LCH) is a group of rare disorders histologically characterized by the proliferation of Langerhans cells. Multiple organs and systems may be involved by the disease. Typically, there is bone involvement and, less frequently, lesions may be found in the lungs, liver, lymph nodes, skin, and mucosa.
Sushma Galgali +3 more
openaire +3 more sources